Market Overview:
The global etopophos market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing awareness about cancer treatments. By type, the capsule segment is expected to account for the largest share of the global etopophos market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period. By application, leukemia is estimated to account for the largest share of the global etopophos market in 2018.
 Industry Outlook.svg)
Product Definition:
Etopophos is a chemotherapeutic agent used in the treatment of various types of cancer. It is a prodrug that is converted to etoposide, an active agent, once it enters the cells. Etopophos is important because it can be used to treat cancers that are resistant to other chemotherapy drugs.
Capsule:
Capsule is a device that contains medicine in it. It protects the medicine from getting into contact with other substances and helps it to deliver the exact dose to where it is needed. The most common type of capsule used by humans are gelatin capsules, which are made from collagen, a protein found in skin and bones of animals such as cattle and pigs. There are also vegetarian capsules available that contain plant-based proteins such as soy protein instead of animal-derived collagen or gelatin.
Powder-injection:
Powder-injection is a method of adding active pharmaceutical ingredients to solid form, which can be further processed as per the requirements. Powder-injection offers several advantages such as it can be easily handled and has longer shelf life than liquid formulations. Moreover, it allows for precise dosing at reduced risk of contamination due to loss of potency caused by exposure to light or moisture.
Application Insights:
The leukemia segment dominated the global etopophos market in terms of revenue share in 2017. This is attributed to the increasing prevalence of cancer types, such as acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). According to data published by WHO, an estimated more than 200,000 people die due to cancer every year. Moreover, new cases of ALL and CML are reported globally each year. For instance, according to statistics published by NCBI around 1230 new cases were registered for ALL worldwide in 2014 while about 740 for CML.
The others application segment includes cancers such as testicular tumor and prostate tumor among others. The rising number of these types of cancer is also a factor contributing towards the overall growth rate for etopophos market during the forecast period from 2018 to 2030 owing to which these segments are expected grow at lucrative rates during this period too.
Regional Analysis:
North America dominated the global etopophos market in 2017. This is attributed to the presence of a large number of manufacturers and suppliers coupled with high awareness levels among consumers. The region is expected to maintain its dominance over the forecast period as well owing to increasing R&D activities by key players for development of novel drugs targeting cancer cells with low toxicity.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidence rates of cancers in this region especially gastrointestinal tract, bladder, and prostate cancer which are highly susceptible due to chronic infection caused by Helicobacter pylori bacteria. This factor has led researchers from Japan’s Tohoku University Graduate School Of Medical Sciences To Conduct Research On Management Of Cancer Stem Cells For Curing H pylori Infection-Caused GITCancer (Abstract).
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for etopophos in the coming years.
- Growing awareness about etopophos: There is a growing awareness about the benefits of etopophos among healthcare professionals and patients alike. This is likely to boost its demand in the near future.
- Rising number of clinical trials: A large number of clinical trials are being conducted on etopophos across the world, which is indicative of its potential as a therapeutic agent against various types of cancers.
- Availability of generic versions: The availability of generic versionsof etopophos has made it more affordable and accessible to patients in developing countries, thereby boosting its demand worldwide.. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Etopophos (CAS 33419-42-0) Market Research Report
By Type
Capsule, Powder-injection
By Application
Leukemia, Testicular Tumor, Bladder Cancer, Prostatic Cancer, Gastric Cancer, Others
By Companies
Abcam, MP Biomedicals, Merck, Perrigo, Himpharm, NIPPON KAYAKU, Novartis, Bristol-Myers Squib
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Etopophos (CAS 33419-42-0) Market Report Segments:
The global Etopophos (CAS 33419-42-0) market is segmented on the basis of:
Types
Capsule, Powder-injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Leukemia, Testicular Tumor, Bladder Cancer, Prostatic Cancer, Gastric Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abcam
- MP Biomedicals
- Merck
- Perrigo
- Himpharm
- NIPPON KAYAKU
- Novartis
- Bristol-Myers Squib
 Market Overview.svg)
Highlights of The Etopophos (CAS 33419-42-0) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Powder-injection
- By Application:
- Leukemia
- Testicular Tumor
- Bladder Cancer
- Prostatic Cancer
- Gastric Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Etopophos (CAS 33419-42-0) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Etopophos is a chemical compound with the molecular formula C8H10N4O2. It is a white solid that is soluble in water and most organic solvents.
Some of the major companies in the etopophos (cas 33419-42-0) market are Abcam, MP Biomedicals, Merck, Perrigo, Himpharm, NIPPON KAYAKU, Novartis, Bristol-Myers Squib.
The etopophos (cas 33419-42-0) market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Etopophos (CAS 33419-42-0) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Etopophos (CAS 33419-42-0) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Etopophos (CAS 33419-42-0) Market - Supply Chain
4.5. Global Etopophos (CAS 33419-42-0) Market Forecast
4.5.1. Etopophos (CAS 33419-42-0) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Etopophos (CAS 33419-42-0) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Etopophos (CAS 33419-42-0) Market Absolute $ Opportunity
5. Global Etopophos (CAS 33419-42-0) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
5.3.1. Capsule
5.3.2. Powder-injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Etopophos (CAS 33419-42-0) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
6.3.1. Leukemia
6.3.2. Testicular Tumor
6.3.3. Bladder Cancer
6.3.4. Prostatic Cancer
6.3.5. Gastric Cancer
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Etopophos (CAS 33419-42-0) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Etopophos (CAS 33419-42-0) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Etopophos (CAS 33419-42-0) Demand Share Forecast, 2019-2026
9. North America Etopophos (CAS 33419-42-0) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
9.4.1. Leukemia
9.4.2. Testicular Tumor
9.4.3. Bladder Cancer
9.4.4. Prostatic Cancer
9.4.5. Gastric Cancer
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
9.7.1. Capsule
9.7.2. Powder-injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Etopophos (CAS 33419-42-0) Demand Share Forecast, 2019-2026
10. Latin America Etopophos (CAS 33419-42-0) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
10.4.1. Leukemia
10.4.2. Testicular Tumor
10.4.3. Bladder Cancer
10.4.4. Prostatic Cancer
10.4.5. Gastric Cancer
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
10.7.1. Capsule
10.7.2. Powder-injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Etopophos (CAS 33419-42-0) Demand Share Forecast, 2019-2026
11. Europe Etopophos (CAS 33419-42-0) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
11.4.1. Leukemia
11.4.2. Testicular Tumor
11.4.3. Bladder Cancer
11.4.4. Prostatic Cancer
11.4.5. Gastric Cancer
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
11.7.1. Capsul
11.7.2. Powder-injection
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Etopophos (CAS 33419-42-0) Demand Share, 2019-2026
12. Asia Pacific Etopophos (CAS 33419-42-0) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
12.4.1. Leukemia
12.4.2. Testicular Tumor
12.4.3. Bladder Cancer
12.4.4. Prostatic Cancer
12.4.5. Gastric Cancer
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
12.7.1. Capsule
12.7.2. Powder-injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Etopophos (CAS 33419-42-0) Demand Share, 2019-2026
13. Middle East & Africa Etopophos (CAS 33419-42-0) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Application
13.4.1. Leukemia
13.4.2. Testicular Tumor
13.4.3. Bladder Cancer
13.4.4. Prostatic Cancer
13.4.5. Gastric Cancer
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Etopophos (CAS 33419-42-0) Market Size and Volume Forecast by Type
13.7.1. Capsule
13.7.2. Powder-injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Etopophos (CAS 33419-42-0) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Etopophos (CAS 33419-42-0) Market: Market Share Analysis
14.2. Etopophos (CAS 33419-42-0) Distributors and Customers
14.3. Etopophos (CAS 33419-42-0) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abcam
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. MP Biomedicals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Perrigo
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Himpharm
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. NIPPON KAYAKU
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squib
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
